A new prescription eye derailment that could allow many people to put their read glasses has been approved by the US Food and Drug Administration (FDA).
The once-daily drop known as Vizz, manufactured by pharmaceutical company Lenz, dealed with age-related blurred myopia (also known as Persbyopia) for up to 10 hours at a time.
Although it is not a permanent solution, users may not need to consistently read glasses nearby or put contact lenses in daily.
Presbyopia is a common condition seen in many people, especially those over the age of 40, and as their vision begins to deteriorate with age, it is becoming more difficult to read words up close. Often they use glasses and contact lens readings, books, phones and other small prints even further apart, increasing the lights and fonts on the screen, even giving them a more clear look.
According to the manufacturer, Vizz works together with the help of a chemical called aceclidine to create a “pinhole effect” on the eyes, narrowing the pupil in a way similar to a camera lens, and bringing the close-up object and text into a clearer focus.
Unlike previously released eye drops, it also helps reduce presbyopia by affecting the eye's focal muscles, but Vizz doesn't cause “zoom-in” effects or blur-distance vision, the company says.
Get weekly health news
Receive the latest medical news and health information provided every Sunday.
Additionally, it claims that the newly approved drops do not cause adverse effects like the weight of the brows due to activation of ciliary muscles.
That doesn't mean that Vizz Eye Drops have no side effects. The FDA guidance states that users may experience temporary dim vision or dark vision after penetration, warning against vague driving or manipulation of vision. There are also warnings to be aware of when driving at night or taking part in other activities in low light.
There were also rare cases of retinal tears and separation, especially in patients with pre-existing retinal diseases, when using myotics.
A certain percentage of patients who used the drug during clinical trials experienced eye irritation (20%) and headache (13%).
Trend now
Loto 6/49 and Lotomax win numbers on Friday and Saturday
Montreal's father was assaulted in front of his children, leading to rage from officials
More Video Details
“This FDA approval represents a disruptive paradigm shift in treatment options for millions of people who are unhappy and struggling with the inevitable age-related loss of vision,” said Mark Blue Center, Vizz clinical investigator from the Schwartz Laser Eye Care Center in Scottsdale, Arizona.
“I think this will be a welcome solution for both optometrists and ophthalmologists who will be able to provide highly effective and sought after erectile erberism treatments that can soon become standard care with a product profile that meets the needs of the patient.”
Global News contacted Health Canada to ask if the agency was trying to approve Vizz for Canadians, but did not respond as in the press time.
A report from Eyes on EyeCare, released this summer, says Lenz Therapeutics has announced that it will help bring exclusive licensing and commercialization agreements to Canada with Théa, a European pharmaceutical company specializing in the research, development and commercialization of ophthalmic products. So far, they say there is no established timeline.
The drug is expected to become widely available in the US by October this year.
The Canadian Association of Optometry refers to the “natural consequence of aging,” which becomes more pronounced as the eyes lose elasticity and flexibility, and usually presents them first between the ages of 40 and 45. Usually, it progresses to your late 40s or early 50s.
Statistics collected by Eye Health Central estimate that around 1.8 billion people live in this state, indicating that the data is more common in North America. However, improving access to Canadian and US eye tests may be expanding numbers.
Curator Recommendations
This is how to clean up summer stains and messes like a pro
Convert space with these wire-free lighting upgrades
&Copy 2025 Global News, a division of Corus Entertainment Inc.